Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression

NCT01284205 is registered in ClinicalTrials.gov with Bioniche Life Sciences Inc. as lead sponsor.

NCT NCT01284205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01284205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression
Lead sponsor
Bioniche Life Sciences Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
January 31, 2010
Completion date
February 28, 2017
Enrollment
0 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer